World immunotherapy conference Oct.30, page-6

Geez that didn't copy and paste well. there is a section in Frederics presentation at Basel....

basically it says, keytruda doesn't help patients with low monocytes, Efti increases monocytes therefore it is likely Efti will assist in making keytruda better able to assist more patients...…..embargo on oral presentation lifted on 9th Nov at SITC for new results for the part A trial.....

If this is good, imagine the possibilities for the 30mg straight up combo.....Another thing, antagonists have an issue with low monocytes,

efti clearly helps in that regard....keytruda is not the only antagonist out there with this issue, I wonder could we see Immutep becoming

more involved with others...….Hopefully a good end of week for the company which should flow onto shareholders....